Fat cells allow melanoma cells to penetrate the dermis, from which they spread, causing fatal metastases in vital organs, TAU researchers say
Researchers at Tel Aviv University, led by Prof. Carmit Levy and Dr. Tamar Golan of the Department of Human Genetics and Biochemistry at TAU’s Sackler School of Medicine, have discovered that fat cells are involved in the transformation that melanoma cells undergo from cancer cells of limited growth in the epidermis to lethal metastatic cells attacking patients’ vital organs.
“We have answered a major question that has preoccupied scientists for years,” explains Prof. Levy. “What makes melanoma change form, turning aggressive and violent? Locked in the skin’s outer layer, the epidermis, melanoma is very treatable; it is still Stage 1, it has not penetrated the dermis to spread through blood vessels to other parts of the body and it can simply be removed without further damage.
“Melanoma turns fatal when it ‘wakes up,’ sending cancer cells to the dermis layer of skin, below the epidermis, and metastasizing in vital organs. Blocking the transformation of melanoma is one of the primary targets of cancer research today, and we now know fat cells are involved in this change.””
The research was conducted in collaboration with several senior pathologists: Dr. Hanan Vaknin of Wolfson Medical Center, and Dr. Dov Hershkowitz and Dr. Valentina Zemer of Tel Aviv Medical Center.
The study was on published July 23 in Science Signaling and is featured on the journal’s cover.
In the study, the researchers examined dozens of biopsy samples taken from melanoma patients at Wolfson Medical Center and Tel Aviv Medical Center, and observed a suspicious phenomenon: fat cells near the tumor sites.
“We asked ourselves what fat cells were doing there and began to investigate,” adds Prof. Levy. “We placed the fat cells on a petri dish near melanoma cells and followed the interactions between them.”
The researchers observed fat cells transferring proteins called cytokines, which affect gene expression, to the melanoma cells.
“Our experiments have shown that the main effect of cytokines is to reduce the expression of a gene called miRNA211, which inhibits the expression of a melanoma receptor of TGF beta, a protein that is always present in the skin,” says Prof. Levy. “The tumor absorbs a high concentration of TGF beta, which stimulates melanoma cells and renders them aggressive.”
Critically, the researchers have also found a way to block this transformation.
“It is important to note that we found the process reversible in the laboratory: When we removed the fat cells from the melanoma, the cancer cells calmed down and stopped migrating,” adds Prof. Levy.
A trial of mouse models of melanoma yielded similar results: When miRNA211 was repressed, metastases were found in other organs, while re-expressing the gene blocked metastases formation.
In the search for a potential drug based on the new discovery, the researchers experimented with therapies that are known to inhibit cytokines and TGF beta, but which have never before been used to treat melanoma.
“We are talking about substances that are currently being studied as possible treatments for pancreatic cancer, and are also in clinical trials for prostate, breast, ovarian and bladder cancers,” Dr. Golan said. “We saw that they restrained the metastatic process, and that the melanoma returned to its relatively ‘calm’ and dormant state.”
“Our findings can serve as a basis for the development of new drugs to halt the spread of melanoma — therapies that already exist, but were never used for this purpose,” concludes Prof. Levy. “In the future, we are seeking to collaborate with drug companies to enhance the development of the metastatic melanoma prevention approach.”
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- Metastatic Melanoma Drug Market Emerging Analysis, Future Growth And Business Opportunities 2026on January 9, 2020 at 11:08 pm
As the competition soars in the global Metastatic Melanoma Drug market, an increasing number of companies are looking exclusive insights into the prevailing trends in the market. Ameco Research study ...
- AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanomaon January 9, 2020 at 9:19 am
Cutaneous malignant melanoma (CMM) is the deadliest form of skin cancer and clinically challenging due to its propensity to develop therapy resistance. Reactive oxygen species (ROS) can induce DNA ...
- Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cellson January 9, 2020 at 2:30 am
The study population consists of 12 melanoma patients and 6 healthy donors (HDs) used as controls. Selected characteristics of all subjects are listed in STable 1. Age at blood draw did not differ ...
- Metastatic Uveal Melanoma Thereapeutics Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2027on January 8, 2020 at 5:19 pm
Ameco Research added new research report to its vast database titled "Global Metastatic Uveal Melanoma Thereapeutics Market 2019" which provides extensive and highly detailed information on the key ...
- Let's Talk About Melanomaon January 8, 2020 at 8:08 am
Whether you’ve just been diagnosed or worry you could have melanoma, you’re probably nervous, confused, and likely scared. We get it: Melanoma is a form of skin cancer that can be life-threatening.
- Melanoma Immunotherapy Enhanced by Targeting Treg Cell Control Proteinon January 8, 2020 at 5:19 am
For some people with advanced melanoma, such treatment has extended survival from months, to years. However, therapy is only effective in about 40% of people with advanced melanoma. Ze’ev Ronai, Ph.D.
- Melanoma can affect all ages: education, protection importanton January 7, 2020 at 8:35 am
Melanoma can affect anyone, even the young. Education and protection are critical, accordng to a Houston dermatologist.
- Study reveals a new approach to enhancing response to immunotherapy in melanomaon January 7, 2020 at 2:01 am
For some people with advanced melanoma, a deadly skin cancer, the treatment has extended survival to years instead of months. However, the treatment only works for about 40% of people with advanced ...
- A new strategy for boosting PD-1 blockers in melanomaon January 7, 2020 at 1:00 am
Immuno-oncology drugs like Bristol-Myers Squibb’s Opdivo and Merck’s Keytruda free up the immune system to attack cancer by blocking the checkpoint PD-1. But in melanoma, at least half of patients don ...
- Lower risk for malignant melanoma after bariatric surgeryon January 3, 2020 at 5:46 am
The surgery group included 23 individuals who developed malignant skin cancer, i.e. squamous cell carcinoma or malignant melanoma, in parallel with marked weight loss. The corresponding figure for ...
via Bing News